이 보고서는 뇌 아밀로이드 혈관병증(CAA)를 자세히 조사하여 진단된 유병 사례, 중증도별 진단된 유병 사례, 성별 진단된 유병 사례, 연령별 진단된 유병 사례 등 과거 및 미래의 역학 데이터를 보여줍니다. 게다가 환자 집단과 관련된 다양한 요소로 진단 프로세스, 처방 패턴, 의사의 견해, 시장 접근, 치료 옵션, 미래 시장 동향을 분석하고 미국, EU 4개국(독일, 프랑스, 이탈리아, 스페인), 영국, 일본의 주요 7시장을 대상으로 2020년부터 2034년까지 시장 규모 추정과 예측을 제공합니다. 또한 본 보고서는 현재의 치료실태 및 미충족 요구를 상세하게 분석하여 시장의 잠재적 가능성 및 치료·개입의 새로운 사업 기회를 밝혀내고 있습니다.
DelveInsight's comprehensive report titled "Cerebral Amyloid Angiopathy (CAA) - Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of CAA. The report presents historical and projected epidemiological data covering Diagnosed Prevalent Cases of CAA, Severity-specific Diagnosed Prevalent Cases of CAA, Gender-specific Diagnosed Prevalent Cases of CAA, and Age-specific Diagnosed Prevalent Cases of CAA. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.
The report analyzes the existing treatment practices and unmet medical requirements in CAA. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.
Cerebral Amyloid Angiopathy (CAA) Overview
CAA is a cerebrovascular condition marked by the buildup of amyloid beta-peptides in the leptomeninges and small to medium cerebral vessels, leading to vessel fragility and potential lobar intracerebral hemorrhage (ICH). It can also manifest as cognitive decline, microbleeds, hemosiderosis, inflammatory white matter changes, Alzheimer's disease, or transient neurological symptoms. CAA may be sporadic or linked to familial syndromes. Diagnosis relies on clinical, imaging, and pathological evidence, with definitive confirmation possible only through postmortem brain examination. No approved disease-modifying therapies exist, and prognosis worsens with larger hemorrhages and advancing age.
Cerebral Amyloid Angiopathy (CAA) Diagnosis and Treatment Overview
CAA diagnosis relies on clinical, radiographic, and pathological criteria. The Boston criteria 2.0 are widely used to assess CAA probability, requiring either brain MRI or biopsy data for definitive diagnosis, though possible and probable diagnoses can be made through clinicoradiological findings. In cases involving lobar intracerebral hemorrhage without MRI, the Edinburgh criteria can guide assessment. For suspected iatrogenic CAA, the modified Queen Square criteria are proposed. Definitive diagnosis remains limited to postmortem examination.
Currently, there are no approved disease-modifying therapies for CAA. Investigational approaches target beta-amyloid clearance through antibody-mediated removal, reduction in production, and enhancement of physiological clearance. These may cause amyloid-related imaging abnormalities (ARIA). Use of anticoagulants and thrombolytics is cautioned due to increased hemorrhage risk, while antiplatelets may be used if clinically indicated. Risk of recurrent hemorrhage is highest within the first three months post-ICH, often occurring near the initial bleed site.
The epidemiology section of the CAA market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.
This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of CAA. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.
Key Findings
The CAA therapeutics market is further expected to increase by the major drivers, such as the rising prevalent population, technological advancements, and upcoming therapies in the forecast period (2025-2034).
CAA currently has no approved disease-modifying therapies, highlighting a major therapeutic gap. Management is largely symptomatic and relies on off-label use of various medications. Clinicians often adopt supportive strategies such as strict blood pressure control, and cautious use of antithrombotics to mitigate hemorrhagic risk. These approaches are tailored to individual patient profiles, though none target the underlying amyloid pathology. The absence of standardized treatments underscores the urgent need for targeted research and novel therapeutic development in CAA.
With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the CAA market in the 7MM is expected to change significantly during the forecast period (2025-2034).
Emerging Drugs
Mivelsiran (ALN-APP): Alnylam Pharmaceuticals
Mivelsiran is an experimental RNA interference (RNAi) therapy administered by intrathecal route and being developed for CAA. Its mechanism involves selectively silencing APP mRNA within the central nervous system, which may lead to reduced production of amyloid precursor protein and its related cleavage products most notably amyloid beta (AB), a key contributor to CAA pathology. By targeting the source of amyloid generation, Mivelsiran aims to address the underlying disease process rather than just the symptoms.
Cerebral Amyloid Angiopathy (CAA) Market Segmentation
DelveInsight's 'Cerebral Amyloid Angiopathy (CAA) - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a detailed outlook of the current and future CAA market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.
Cerebral Amyloid Angiopathy (CAA) Market Size by Countries
The CAA market size is assessed separately for various countries, including the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) CAA market, primarily attributed to the country's higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.
Cerebral Amyloid Angiopathy (CAA) Market Size by Therapies
CAA Market Size by Therapies is categorized into current and emerging markets for the study period 2020-2034.
This section focuses on the sales uptake of potential CAA drugs that have recently been launched or are anticipated to be launched in the CAA market between 2025 and 2034. It estimates the market penetration of CAA drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the CAA market.
The emerging CAA therapies are analyzed based on various attributes such as efficacy and safety in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the CAA market.
Cerebral Amyloid Angiopathy (CAA) Market Access and Reimbursement
DelveInsight's "Cerebral Amyloid Angiopathy (CAA) - Market Insights, Epidemiology, and Market Forecast - 2034" report provides a descriptive overview of the market access and reimbursement scenario of CAA. This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.
KOL Views
To keep up with current CAA market trends and to fill gaps in secondary findings, we interview KOLs' and SMEs' working in the CAA domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or CAA market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the CAA unmet needs.
Cerebral Amyloid Angiopathy (CAA): KOL Insights
DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as, Massachusetts General Hospital, US, Department of Medicine and Surgery, University of Perugia, Italy; Goethe University, Germany; Institute of Prion Diseases, United Kingdom; Kumamoto University, Kumamoto, Japan, Hirosaki University Graduate School of Medicine, Japan among others.
"CAA remains a major unmet medical need due to the absence of approved disease-modifying therapies. Current management is limited to symptom control, lacking interventions that address the underlying pathology. There's a pressing demand for targeted treatments, early diagnostic tools, and better risk stratification approaches."
"Clinicians should remain vigilant for symptoms such as new-onset headaches, seizures, focal neurological deficits, and acute or subacute cognitive changes, which may signal inflammatory CAA and warrant immediate evaluation and treatment."
"Treatment focuses on managing symptoms, controlling blood pressure, preventing intracerebral hemorrhage, and avoiding anticoagulants. Supportive care, patient monitoring, and secondary stroke prevention are emphasized. Emerging therapies are under investigation, but none are yet established or approved for CAA treatment."
Competitive Intelligence Analysis
We conduct a Competitive and Market Intelligence analysis of the CAA. Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.
Cerebral Amyloid Angiopathy (CAA) Pipeline Development Activities
The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for CAA. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.
Pipeline Development Activities
The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging CAA therapies.
Treatment goals for CAA focus on minimizing cerebral hemorrhage risk, managing associated cognitive decline, and preserving neurological function. Supportive care involves blood pressure control and avoidance of anticoagulants where possible. Monitoring disease progression and addressing coexisting conditions like Alzheimer's are crucial. While no disease-modifying therapy exists, emerging research targets amyloid clearance and vascular protection to slow progression and improve quality of life.
Managing CAA is complex due to the lack of disease-modifying treatments and difficulties in early diagnosis. Risks of intracerebral hemorrhage limit therapeutic options, especially anticoagulation. Overlapping symptoms with other neurodegenerative disorders hinder clinical distinction. Monitoring disease progression remains difficult, and individualized care is essential. Moreover, balancing stroke prevention with bleeding risk presents ongoing clinical dilemmas, making effective long-term management a major challenge.
CAA market is expanding due to rising awareness, increasing elderly population, and the growing recognition of its link to Alzheimer's disease. Advances in neuroimaging and biomarkers are enabling earlier diagnosis and targeted research. Unmet clinical needs and the absence of disease-modifying therapies are prompting pharmaceutical innovation. Supportive policy changes and growing investment in neurological disorders further catalyze market growth and therapeutic exploration.
The CAA Market and Epidemiology Forecast Report offers clients strategic insights into disease prevalence, patient segmentation, and market dynamics. It helps identify commercial opportunities, assess treatment gaps, and support planning for product development, market entry, or expansion. The report also aids stakeholders in understanding regulatory landscapes, forecasting trends, and making data-driven investment or policy decisions.